↓ Skip to main content

Dove Medical Press

Article Metrics

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date

Overview of attention for article published in Therapeutics and Clinical Risk Management, September 2020
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
17 Mendeley
Title
<p>Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date</p>
Published in
Therapeutics and Clinical Risk Management, September 2020
DOI 10.2147/tcrm.s258704
Pubmed ID
Authors

Sarah Bassiony, Claire N Harrison, Donal P McLornan

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 3 18%
Student > Bachelor 2 12%
Professor > Associate Professor 2 12%
Student > Ph. D. Student 1 6%
Student > Master 1 6%
Other 2 12%
Unknown 6 35%
Readers by discipline Count As %
Medicine and Dentistry 8 47%
Pharmacology, Toxicology and Pharmaceutical Science 2 12%
Immunology and Microbiology 1 6%
Unknown 6 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2020.
All research outputs
#15,434,871
of 17,464,602 outputs
Outputs from Therapeutics and Clinical Risk Management
#1,003
of 1,101 outputs
Outputs of similar age
#322,563
of 383,037 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#1
of 1 outputs
Altmetric has tracked 17,464,602 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,101 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 383,037 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them